Innoviva, Inc. (INVA) stock
Close on Nov 12, 2026Market cap $1.37BP/E 9.6Yield –
Innoviva, Inc. grew revenue 12.8% to $438.32M over the twelve months to Sep 30, 2026. Operating income rose 1.3% to $170.15M, moving the operating margin from 43.2% to 38.8%. Free cash flow was $182.51M, down 9.0% from a year earlier. At the latest close the market valued the company at $1.37B, 9.6 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.37B
- P/E ratio
- 9.6
- Price to sales
- 3.13
- Price to book
- 1.20
- Dividend yield
- –
- Free cash flow yield
- 13.32%
Fundamentals
- Revenue
- $438.32M
- EPS, diluted
- $1.97
- Free cash flow
- $182.51M
- Book value per share
- $15.78
- Diluted shares
- 72M
Trading
- Next earnings
- Feb 24, 2027 (estimated, during market hours)
- Previous close
- $18.86
- Open
- $18.99
- Day's range
- $18.86 – $19.24
- Volume
- 563,822
- Average volume (20 days)
- 861,615
- Index membership
- S&P SmallCap 600, Russell 2000, Russell 3000
- Beta (5 years)
- 0.23
- 52-week range
- $18.66 – $25.14
- RSI (14 days)
- 32.0
- Volatility (1 year)
- 25.2%
- Relative volume
- 0.69×
- WACC
- 7.3%
On 1 of our idea list: Buyback cannibals
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | INVA | S&P 500 | Difference | INVA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -11.6% | -2.7% | −8.9 pts | ||
| 3 months | -8.8% | -1.7% | −7.1 pts | ||
| Year to date | -5.1% | +11.9% | −17.0 pts | ||
| 1 year | -14.9% | +12.0% | −26.8 pts | ||
| 3 years | +40.8% | +78.2% | −37.3 pts | +12.1% | +21.2% |
| 5 years | +6.8% | +73.2% | −66.4 pts | +1.3% | +11.6% |
| 10 years | +73.4% | +309.6% | −236.2 pts | +5.7% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
EPS, diluted
Free cash flow
Press releases
Releases Innoviva filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About Innoviva
Pharmaceutical Preparations
Innoviva, Inc. is a biopharmaceutical company that manages a portfolio of royalty-bearing medicines, critical care therapies, and healthcare assets. Its business focuses on two primary areas: commercializing specialty treatments and licensing respiratory medications. The company’s partnered portfolio includes respiratory drugs RELVAR/BREO ELLIPTA and ANORO ELLIPTA. Through its critical care and infectious disease platform, Innoviva provides hospital-focused therapies such as GIAPREZA for distributive shock, XACDURO for bacterial pneumonia, XERAVA for intra-abdominal infections, ZEVTERA for severe bacterial conditions, and NUZOLVENCE for gonorrhea. These products serve healthcare institutions, medical professionals, and patients being treated for acute infections, respiratory conditions, and critical illnesses.
Company profile, executives and historyInnoviva stock: common questions
What is Innoviva's stock price?
INVA closed at $18.97 on Nov 12, 2026, up 0.58% on the day. Over the past 52 weeks it traded between $18.66 and $25.14.
What is Innoviva's market cap?
Innoviva was worth $1.37B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is INVA's P/E ratio?
INVA trades at 9.6 times earnings, based on diluted earnings per share of $1.97 over the twelve months to Sep 30, 2026.
How much revenue does Innoviva make?
Innoviva reported revenue of $438.32M for the twelve months to Sep 30, 2026, up 12.8% from a year earlier.
Does Innoviva pay a dividend?
No. Innoviva has not paid a cash dividend over the last twelve months.
When does Innoviva report earnings next?
Innoviva is expected to report Q4 FY2026 results on Feb 24, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has INVA stock performed over the past year?
Including dividends, INVA returned -14.9% over the past year, against +12.0% for the S&P 500.
How many INVA shares are sold short?
7M shares were sold short at the latest FINRA report, 10.96% of the float, or 12.9 days of average trading volume.
Who are Innoviva's competitors?
Companies most similar to Innoviva by business, industry and size include LQDA, INSM, PHAR, MIRM, AAPG.
See a number that looks wrong?